The 2015 ASRA guidelines categorize procedures depending on their risk: high risk, intermediate risk, and low risk.
These findings highlight an urgent need to produce more evidence on the risks and benefits of off-label antidepressant use.
Peripheral anti-nociceptive effects of Substance P
Finding supports naloxone prescriptions for patients taking opioids for chronic pain
Pharmacogenetic testing yields information that informs how an individual will metabolize medications.
Many adults take five or more medications, often for preventable ills.
Naloxegol functions as a peripherally acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids.
Epilepsy drug Spritam may be one of many custom-made medicines to come that will use the technology.
For Echo, reducing the therapeutic dose is key to improving compliance and providing both patients and healthcare providers with a more cost-effective therapy.
Clinical and community-based approaches should be used to increase aspirin use among low-use groups.
No indication any particular type of antidepressant carries a greater risk than others.
Clinical Pain Advisor Articles
- Transcranial Random Noise Stimulation Effective on Multiple Fibromyalgia-Associated Symptoms
- Comparing Dry Needling, Cortisone for Greater Trochanteric Pain Syndrome
- Vestibular Rehabilitation an Effective Treatment for Vestibular Migraine
- Secondary Hyperalgesia Mediated by Nociceptive and Other Sensory Pathways
- Naloxone: Policies and Access